Table 1.
Baseline characteristics of included studies.
| Study | N (T/C) | Physical | Stage | Interventions | Outcomes | |
|---|---|---|---|---|---|---|
| T | C | |||||
| Liang et al., 2016 [18] | 39/39 | KPS ≥ 60 | III-IV | DP + SFI (80 ml/d, d1–d10) | DP | ⑦ |
| Wang et al., 2016 [19] | 96/96 | PS ≤ 2 | IIIb-IV | GP + SFI (100 ml/d, d1–d15) | GP | ①②③④⑤ |
| Zhang, 2015 [20] | 64/64 | NR | III-IV | GP + SFI (60 ml/d, d1–d21) | GP | ①⑦ |
| Xie et al., 2015 [21] | 40/40 | PS ≤ 2 | III-IV | TP + SFI (80 ml/d, d1–d7) | TP | ②④⑤ |
| Bai et al., 2014 [22] | 39/39 | KPS ≥ 60 | III-IV | DP + SFI (80 ml/d, d1–d10) | DP | ①②③④⑤⑥ |
| Li, 2014 [23] | 30/30 | PS ≤ 2 | III-IV | NP + SFI (50 ml/d, d1–d10) | NP | ①⑥ |
| Chen and Zhao, 2013 [24] | 40/36 | KPS ≥ 60 | IIIb-IV | GP + SFI (30 ml/d, d1–d14) | GP | ②④⑤ |
| Gao et al., 2008 [25] | 43/43 | KPS ≥ 60 | III-IV | GP + SFI (60 ml/d, d1–d10) | GP | ①②③④⑤⑥ |
| Hu, 2011 [26] | 19/19 | PS ≤ 2 | III-IV | GP + SFI (60 ml/d, d1–d9) | GP | ②③④ |
| Jiang et al., 2011 [27] | 38/38 | KPS ≥ 60 | III-IV | NP + SFI (60 ml/d, d1–d10) | NP | ⑦ |
| Liu and Huang, 2011 [28] | 30/30 | KPS ≥ 70 | III-IV | NP + SFI (60 ml/d, d1–d14) | NP | ⑥ |
| Lu et al., 2011 [29] | 30/30 | KPS ≥ 60 | III-IV | NP + SFI (60 ml/d, d1–d10) | NP | ①②④⑤⑦ |
| Liu and Zhang, 2010 [30] | 18/19 | PS ≤ 2 | IIIb-IV | TP + SFI (60 ml/d, d1–d14) | TP | ①②③④⑤ |
| Chen, 2010 [31] | 24/23 | NR | III-IV | NP + SFI (50 ml/d, d1–d10) | NP | ①②③④⑤ |
| Xie et al., 2010 [32] | 25/25 | KPS ≥ 60 | III-IV | NP + SFI (50 ml/d, 1–d10) | NP | ②③④⑤ |
| Zhang et al., 2009 [33] | 31/28 | KPS ≥ 60 | IIIb-IV | GC + SFI (60 ml/d, d1–d10) | GC | ①②③④⑤⑦ |
| Liu, 2008 [34] | 21/20 | KPS ≥ 60 | III-IV | GP + SFI (50 ml/d, d1–d10) | GP | ②③④⑤ |
| Li et al., 2008 [35] | 26/28 | KPS ≥ 70 | IIIb-IV | TC + SFI (100 ml/d, d1–d7) | TC | ① |
| Tang et al., 2008 [36] | 18/19 | KPS ≥ 60 | IIIb-IV | NP + SFI (60 ml/d, d1–d7) | NP | ①⑤⑥ |
| Liu et al., 2008 [37] | 35/35 | PS ≤ 2 | IIIb-IV | TP + SFI (40–60 ml/d, d1–d10) | TP | ⑦ |
| Gong and Luo, 2008 [38] | 30/30 | KPS ≥ 50 | IIIb-IV | NP + SFI (50 ml/d, d1–d14) | NP | ①②③④ |
| Lu et al., 2005 [39] | 36/29 | KPS ≥ 60 | IIIb-IV | TP + SFI (50 ml/d, d1–d14) | TP | ②③④ |
| Liu et al., 2004 [40] | 21/21 | KPS ≥ 60 | IIIb-IV | NP + SFI (50 ml/d, d1–d14) | NP | ①②④ |
N, number of participants; T, treatment; C, control; KPS, Karnofsky performance score; PS, performance status; SFI, Shenfu injection; NR, not reported; DP, docetaxel + platinum; GP, gemcitabine + platinum; TP, taxol + platinum; NP, navelbine + platinum; GC, gemcitabine + cisplatin; TC, taxol + cisplatin; ① objective tumor response; ② white blood cell toxicity; ③ hemoglobin toxicity; ④ platelet toxicity; ⑤ vomiting toxicity; ⑥ KPS; ⑦ immune function.